Mrs Joyce T Callis, LMFT | |
250 S Pleasantburg Dr, Greensville, SC 29607 | |
(864) 423-8765 | |
Not Available |
Full Name | Mrs Joyce T Callis |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 250 S Pleasantburg Dr, Greensville, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639206998 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | SC3818 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Joyce T Callis, LMFT 14 St Thomas Court, Greer, SC 29651 Ph: (864) 423-8765 | Mrs Joyce T Callis, LMFT 250 S Pleasantburg Dr, Greensville, SC 29607 Ph: (864) 423-8765 |
News Archive
OPKO Health, Inc., has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
Adults at risk for type 2 diabetes or heart disease or both can substantially increase their physical activity levels through participating in a lifestyle intervention program developed at the University of Pittsburgh Graduate School of Public Health for use in community-settings, such as senior centers or worksites.
The National Institute of Environmental Health Sciences (NIEHS) has awarded a five-year, $1.5 million grant extension to Columbia University's Mailman School of Public Health to fund research into the function of a biomarker for brain injury called Translocator Protein 18 kDa, better known as TSPO, in order to better understand its function in brain injury and inflammation and discover targets for therapy.
Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.
› Verified 6 days ago